162 related articles for article (PubMed ID: 23293739)
1. Value of drug level testing and antibody assays in optimising biological therapy.
Vermeire S; Gils A
Frontline Gastroenterol; 2013 Jan; 4(1):41-43. PubMed ID: 23293739
[No Abstract] [Full Text] [Related]
2. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.
Papamichael K; Afif W; Drobne D; Dubinsky MC; Ferrante M; Irving PM; Kamperidis N; Kobayashi T; Kotze PG; Lambert J; Noor NM; Roblin X; Roda G; Vande Casteele N; Yarur AJ; Arebi N; Danese S; Paul S; Sandborn WJ; Vermeire S; Cheifetz AS; Peyrin-Biroulet L;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):171-185. PubMed ID: 35026171
[TBL] [Abstract][Full Text] [Related]
3. Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy.
Mehrling T; Soltis D
Antibodies (Basel); 2018 Feb; 7(1):. PubMed ID: 31544863
[TBL] [Abstract][Full Text] [Related]
4. Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation.
Tikhonova IA; Yang H; Bello S; Salmon A; Robinson S; Hemami MR; Dodman S; Kharechko A; Haigh RC; Jani M; McDonald TJ; Hoyle M
Health Technol Assess; 2021 Feb; 25(8):1-248. PubMed ID: 33555998
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of a pre-treatment procedure to eliminate human monoclonal antibody therapeutic drug and matrix interference in cell-based functional neutralizing antibody assays.
Xu W; Jiang H; Titsch C; Haulenbeek JR; Pillutla RC; Aubry AF; DeSilva BS; Arnold ME; Zeng J; Dodge RW
J Immunol Methods; 2015 Jan; 416():94-104. PubMed ID: 25445325
[TBL] [Abstract][Full Text] [Related]
6. Correction: Mehrling, T.; et al. Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy.
Mehrling T; Soltis D;
Antibodies (Basel); 2018 Aug; 7(3):. PubMed ID: 31544883
[TBL] [Abstract][Full Text] [Related]
7. Upfront acid treatment with low final pH: the development and testing of a novel method to improve drug tolerance in antidrug antibody assays.
Mack JK; Bivi N
Bioanalysis; 2023 Oct; 15(19):1179-1191. PubMed ID: 37638871
[No Abstract] [Full Text] [Related]
8. Optimising the accuracy of HIV drug resistance assays.
Karim SSA
Lancet HIV; 2018 Nov; 5(11):e608-e609. PubMed ID: 30282604
[No Abstract] [Full Text] [Related]
9. Diagnostic performance of Food and Drug Administration-cleared serologic assays for natural rubber latex-specific IgE antibody. The Multi-Center Latex Skin Testing Study Task Force.
Hamilton RG; Biagini RE; Krieg EF
J Allergy Clin Immunol; 1999 May; 103(5 Pt 1):925-30. PubMed ID: 10329830
[TBL] [Abstract][Full Text] [Related]
10. Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays.
Nice R; Chanchlani N; Green H; Bewshea C; Ahmad T; Goodhand JR; McDonald TJ; Perry MH; Kennedy NA
Aliment Pharmacol Ther; 2021 Jan; 53(1):128-137. PubMed ID: 33226651
[TBL] [Abstract][Full Text] [Related]
11. Assays for measurement of TNF antagonists in practice.
Vande Casteele N
Frontline Gastroenterol; 2017 Oct; 8(4):236-242. PubMed ID: 29067148
[TBL] [Abstract][Full Text] [Related]
12. Development of a core outcome set for effectiveness trials aimed at optimising prescribing in older adults in care homes.
Millar AN; Daffu-O'Reilly A; Hughes CM; Alldred DP; Barton G; Bond CM; Desborough JA; Myint PK; Holland R; Poland FM; Wright D;
Trials; 2017 Apr; 18(1):175. PubMed ID: 28403876
[TBL] [Abstract][Full Text] [Related]
13. Advancing the cybersecurity of the healthcare system with self-optimising and self-adaptative artificial intelligence (part 2).
Radanliev P; De Roure D
Health Technol (Berl); 2022; 12(5):923-929. PubMed ID: 35975178
[TBL] [Abstract][Full Text] [Related]
14. Field comparison of circulating antibody assays versus circulating antigen assays for the detection of schistosomiasis japonica in endemic areas of China.
Cai YC; Xu JF; Steinmann P; Chen SH; Chu YH; Tian LG; Chen MX; Li H; Lu Y; Zhang LL; Zhou Y; Chen JX
Parasit Vectors; 2014 Mar; 7():138. PubMed ID: 24684924
[TBL] [Abstract][Full Text] [Related]
15. A rapid lateral flow immunoassay for identity testing of biotherapeutics.
Machiesky L; Côté O; Kirkegaard LH; Mefferd SC; Larkin C
J Immunol Methods; 2019 Nov; 474():112666. PubMed ID: 31525363
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Three Commercial SARS-CoV-2 Serologic Assays and Their Performance in Two-Test Algorithms.
Turbett SE; Anahtar M; Dighe AS; Garcia Beltran W; Miller T; Scott H; Durbin SM; Bharadwaj M; Thomas J; Gogakos TS; Astudillo M; Lennerz J; Rosenberg ES; Branda JA
J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 33020186
[TBL] [Abstract][Full Text] [Related]
17. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
Mitrev N; Vande Casteele N; Seow CH; Andrews JM; Connor SJ; Moore GT; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; van Langenberg D; Ward MG; Leong RW;
Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1037-1053. PubMed ID: 29027257
[TBL] [Abstract][Full Text] [Related]
18. Recommendations for the development and validation of confirmatory anti-drug antibody assays.
Jani D; Marsden R; Mikulskis A; Gleason C; Klem T; Krinos Fiorotti C; Myler H; Yang L; Fiscella M
Bioanalysis; 2015; 7(13):1619-31. PubMed ID: 26226311
[TBL] [Abstract][Full Text] [Related]
19. Strategies for screening young stock for antibodies - optimising numbers to test, cut-points, & predictive values for bovine viral diarrhoea virus.
Humphry RW; Reeves A; Gunn GJ
Sci Rep; 2018 Jun; 8(1):9532. PubMed ID: 29934642
[TBL] [Abstract][Full Text] [Related]
20. Testing human biologicals in animal host resistance models.
Burleson GR; Burleson FG
J Immunotoxicol; 2008 Jan; 5(1):23-31. PubMed ID: 18382855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
